Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) EBITDA (2016 - 2020)

Historic EBITDA for Phio Pharmaceuticals (PHIO) over the last 9 years, with Q4 2020 value amounting to -$2.5 million.

  • Phio Pharmaceuticals' EBITDA rose 775.57% to -$2.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$8.8 million, marking a year-over-year increase of 215.87%. This contributed to the annual value of -$11.5 million for FY2022, which is 1516.54% up from last year.
  • As of Q4 2020, Phio Pharmaceuticals' EBITDA stood at -$2.5 million, which was up 775.57% from -$2.3 million recorded in Q3 2020.
  • Phio Pharmaceuticals' 5-year EBITDA high stood at -$1.5 million for Q3 2018, and its period low was -$7.1 million during Q1 2017.
  • In the last 5 years, Phio Pharmaceuticals' EBITDA had a median value of -$2.2 million in 2016 and averaged -$2.4 million.
  • Per our database at Business Quant, Phio Pharmaceuticals' EBITDA crashed by 21541.2% in 2017 and then skyrocketed by 6838.02% in 2018.
  • Over the past 5 years, Phio Pharmaceuticals' EBITDA (Quarter) stood at -$2.3 million in 2016, then grew by 14.88% to -$2.0 million in 2017, then grew by 12.91% to -$1.7 million in 2018, then crashed by 53.92% to -$2.7 million in 2019, then increased by 7.76% to -$2.5 million in 2020.
  • Its EBITDA was -$2.5 million in Q4 2020, compared to -$2.3 million in Q3 2020 and -$1.7 million in Q2 2020.